SUBCUVIA 160 g/l. Solution for injection アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

subcuvia 160 g/l. solution for injection

baxalta innovations gmbh - human plasma protein >95% immunoglobulins - solution for injection - 160 gram(s)/litre - immunoglobulins, normal human; immunoglobulins, normal human, for extravascular adm. - immune sera and immunoglobulins: immunoglobulins, normal human, for extravascular administration - replacement therapy in adults and children in primary immunodeficiency syndromes such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia - common variable immunodeficiency - severe combined immunodeficiency - igg subclass deficiencies with recurrent infections

Albunorm 20%, 200g/l, solution for infusion アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

albunorm 20%, 200g/l, solution for infusion

octapharma (ip) sprl - human plasma protein not containing less than 96% human albumin - solution for infusion - 200 gram(s)/litre - blood substitutes and plasma protein fractions; albumin

Albunorm 5%, 50 g/l, solution for infusion アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

albunorm 5%, 50 g/l, solution for infusion

octapharma (ip) sprl - human plasma protein not containing less than 96% human albumin - solution for infusion - 50 gram(s)/litre - blood substitutes and plasma protein fractions; albumin

Intratect 100 g/L, solution for infusion アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

intratect 100 g/l, solution for infusion

biotest pharma gmbh - human plasma protein - solution for infusion - 100 gram(s)/litre - immunoglobulins, normal human; immunoglobulins, normal human, for intravascular adm.

Intratect 50 g/L, solution for infusion アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

intratect 50 g/l, solution for infusion

biotest pharma gmbh - human plasma protein >96% immunoglobulins - solution for infusion - 50 gram(s)/litre - immunoglobulins, normal human; immunoglobulins, normal human, for intravascular adm.

CSL ZOSTER IMMUNOGLOBULIN VF (human) 200IU injection vial オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

csl zoster immunoglobulin vf (human) 200iu injection vial

csl behring australia pty ltd - human immunoglobulin g, quantity: 160 mg/ml; zoster immunoglobulin, quantity: 200 iu - injection, solution - excipient ingredients: water for injections; glycine; human immunoglobulin a - indications as at 8 august 2002 : zoster immunoglobulin is indicated for prophylaxis against varicella in patients who meet all four of the criteria listed below: 1. one of the following underlying illnesses or conditions: a. neoplastic disease (leukaemia or lymphoma); b. congenital or acquired immunodeficiency; c. immunosuppressive therapy with steroids or antimetabolites. 2. one of the following types of exposure to chickenpox or shingles patients: a. household contact; b. playmate contact (>1 hour play indoors); c. hospital contact (in same 2 to 4 bedroom or adjacent beds in a large ward); d. newborn contact (newborn of mother who had onset of chickenpox <5 days before delivery or within 48 hours after delivery); e. premature infant (>= 28 weeks gestation) whose mother lacks a prior history of chickenpox; f. premature infant (< 28 weeks gestation or <= 1000g) regardless of maternal history. 3. negative or unknown history of chickenpox. 4. if zoster immunoglobulin can be administered within 96 hours after exposure. zoster immunoglobulin, normal immunoglobulin (immunoglobulin for intramuscular use) or plasma are of no value in the treatment of established varicella or zoster infection. high levels of circulating antibody do not prevent dissemination of infection. zoster immunoglobulin is not indicated for prophylactic use in immunodeficient children or adults when there is a history of varicella, unless the patient's immunosuppressed status is that which is associated with bone marrow transplantation.

FLEXBUMIN 200 G/L SOLUTION FOR INFUSION 200 g/l Solution for Infusion アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

flexbumin 200 g/l solution for infusion 200 g/l solution for infusion

baxter healthcare limited - human plasma protein - solution for infusion - 200 g/l

GAMMABULIN S/D 10ML HUMAN NORMAL IMMUNOGLOBULIN 1.6g/10ml %w/v Solution for Injection アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

gammabulin s/d 10ml human normal immunoglobulin 1.6g/10ml %w/v solution for injection

baxter healthcare limited - human plasma protein >90% gamma globulin - solution for injection - 1.6g/10ml %w/v

TETABULIN %v/v Solution for Injection アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

tetabulin %v/v solution for injection

baxter healthcare limited - human plasma protein >90% gamma globulin human tetanus immunoglobulin ph. eur. - solution for injection - %v/v

Silgard 欧州連合 - 英語 - EMA (European Medicines Agency)

silgard

merck sharp dohme ltd - human papillomavirus type 6 l1 protein, human papillomavirus type 11 l1 protein, human papillomavirus type 16 l1 protein, human papillomavirus type 18 l1 protein - papillomavirus infections; uterine cervical dysplasia; condylomata acuminata; immunization - vaccines - silgard is a vaccine for use from the age of 9 years for the prevention of:premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic human papillomavirus (hpv) types;genital warts (condyloma acuminata) causally related to specific hpv types.see sections 4.4 and 5.1 for important information on the data that support this indication.the use of silgard should be in accordance with official recommendations.